Clinical trials: Diabetes Type I
Type 1 Diabetes Mellitus
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus on Basal Plus Mealtime Insulin
Primary Objective: To compare the glucose control during treatment with a new formulation of insulin glargine and Lantus in adult participants with type 1 diabetes mellitus Secondary Objectives: To compare a new formulation of…
- Trial name
- NCT01658579
- Testing
- HOE901-U300 (new formulation of insulin glargine), Lantus (insulin glargine)
- Where
- 3 sites in United States
- Volunteers
- 59 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Pharmacokinetics, Pharmacodynamics, and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus
The purpose of this study is to determine the pharmacokinetic and safety profile of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus.
- Trial name
- NCT00957268
- Testing
- Alogliptin
- Where
- 7 sites in United States
- Volunteers
- 46 people
- Sponsor
- Takeda
Type 1 Diabetes
DIATOR-Diabetes Intervention With Atorvastatin
Clinical studies have shown that immunomodulators (like Anti-CD3 antibodies) have effects on beta-cell-preservation. The lipid-lowering agent atorvastatin is also a potent immunomodulator.
- Trial name
- NCT00974740
- Testing
- Atorvastatin
- Where
- 12 sites in Germany
- Volunteers
- 63 people
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
Diabetes Mellitus, Type 1
A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)
This study compares insulin icodec (a new insulin) to insulin degludec (an insulin already available on the market) in people with type 1 diabetes.
- Trial name
- ONWARDS 6 (NCT04848480)
- Testing
- insulin icodec, insulin degludec, insulin aspart
- Where
- 130 sites in United States, Austria and 10 more
- Volunteers
- 582 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Efficacy and Safety of Levemir® Used as Basal Insulin
This study is conducted in Europe. The aim of this study is to evaluate efficacy and safety of insulin detemir (Levemir®) used as basal insulin on the glycaemic control, weight and incidence of hypoglycaemic events in insulin…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01548248
- Testing
- insulin detemir, insulin aspart
- Where
- Slovakia
- Volunteers
- 631 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Efficacy and Safety of Insulin Detemir in Type 1 Diabetes
This trial is conducted in Europe. The aim of this trial is to compare the efficacy and safety of insulin detemir and insulin NPH in adults with type 1 diabetes on blood glucose control.
- Trial name
- NCT00595374
- Testing
- insulin detemir, insulin NPH, insulin aspart
- Where
- 18 sites in Netherlands
- Volunteers
- 114 people
- Sponsor
- Novo Nordisk A/S
Diabetic Foot Ulcer, Type 1 Diabetes Mellitus
Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.
The goal of this investigational study is to evaluate the safety and clinical performance of Tropocells Autologous Platelet-rich Fibrin (PRF) for wound care for both males and females, ages 18-80 years old, with Grade 1 and 2…
- Conditions
- Diabetic Foot Ulcer, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus (T2DM), Neuroischemic Foot Ulcer
- Trial name
- NCT06810726
- Testing
- Platelet Rich Plasma
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Estar Medical dba Medical Technologies, LTD
Diabetes Mellitus, Type 1
A Study for Patients With Type 1 Diabetes Mellitus
The purpose of the study is to compare the human insulin inhalation powder plus insulin glargine with injected insulin (regular human insulin or insulin lispro) plus insulin glargine on lowering the blood sugar level.
- Trial name
- NCT00447213
- Testing
- Insulin glargine, Human Insulin Inhalation Powder, Injectable Insulin
- Where
- 5 sites in Japan, Taiwan
- Volunteers
- 70 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
Test of the Efficacy and Safety of Insulin Glulisine Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus
Primary Objective: To evaluate the efficacy and the safety of insulin glulisine in type I Diabetes Melittus (DM) patients Secondary Objective: To evaluate the insulin glulisine doses To assess the patient satisfaction
- Trial name
- PORTAL 1 (NCT00964574)
- Testing
- INSULIN GLULISINE (HMR1964), INSULIN GLARGINE
- Where
- Belarus
- Volunteers
- 68 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 2
Observational Study to Observe the Safety of Levemir® Treatment in Children and Adolescents With Type 1 Diabetes
This observational study is conducted in Europe. The trial aims to observe the incidence of serious adverse drug reactions in children and adolescents with type 1 diabetes during Levemir® treatment.
- Trial name
- PREDICTIVE™ (NCT00704574)
- Testing
- insulin detemir
- Where
- Sweden
- Volunteers
- 159 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
BD FlowSmart™ Subcutaneous Insulin Infusion Set User Preference and Claims Study
Continuous Subcutaneous Insulin Infusion (CSII) via insulin pump therapy has been shown to improve quality of life and glucose control in many patients with diabetes opting for this treatment modality.
- Trial name
- NCT02662842
- Testing
- FlowSmart Infusion Set, Current Infusion Set
- Where
- 4 sites in United States
- Volunteers
- 75 people
- Sponsor
- Becton, Dickinson and Company
Diabetes, Diabetes Mellitus, Type 1
NovoLet® Surveillance Study on Using Human Insulin System in Indonesia
This study is conducted in Asia. The aim of this study is to investigate the safety and efficacy of NovoLet® human insulin delivery system in an outpatient setting.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01492153
- Testing
- biphasic human insulin, isophane human insulin, human soluble insulin
- Where
- Indonesia
- Volunteers
- 1,981 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
Control-IQ Observational (CLIO) Post-Approval Study
Post-approval 522 study designed to collect primarily safety data on the US FDA-cleared product, t:slim X2 insulin pump with Control-IQ technology (Control-IQ system).
- Trial name
- CLIO (NCT04503174)
- Testing
- t:slim X2 pump with Control-IQ technology
- Where
- United States
- Volunteers
- 3,157 people
- Sponsor
- Tandem Diabetes Care, Inc.
Type 1 or Type 2 Diabetes
Evaluate the Safety and Efficacy of Sinocare CGM System Regarding Real Time Glucose Level Monitoring
From Jan 2022 to June 2022, 120 subjects (22-75 years of age, mean ±standard deviation [SD] of 53.20 ±14.49 years) with type 1 or type 2 diabetes participated in the study in P.R. China.
- Trial name
- NCT05995756
- Where
- 3 sites in China
- Volunteers
- 120 people
- Sponsor
- Sinocare
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study
This is a randomized, double-blind, double-dummy, placebo-controlled, cross over design trial with empagliflozin compared to placebo that is added to open-label ramipril.
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Obesity
- Trial name
- NCT02632747
- Testing
- Empagliflozin, ramipril
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- Boehringer Ingelheim
Healthy, Prediabetic State (IGT)
Noninvasive Transcutaneous Glucometer Development
The objective of this study is to assist in the development of a noninvasive device for the accurate measurement of blood glucose levels.
- Conditions
- Healthy, Prediabetic State (IGT), Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
- Trial name
- NCT01168076
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- InLight Solutions
Type 1 Diabetes Mellitus
Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes
The purpose of this study is to determine if adding dapagliflozin to insulin is a safe and effective therapy to improve glycemic control in patients with type 1 diabetes.
- Trial name
- DEPICT 2 (NCT02460978)
- Testing
- Dapagliflozin
- Where
- 136 sites in United States, Argentina and 11 more
- Volunteers
- 815 people
- Sponsor
- AstraZeneca
Atherosclerosis, Diabetes Mellitus
TART - Troglitazone Atherosclerosis Regression Trial
The purpose of this study is to determine if troglitazone reduces the progression of early preintrusive carotid atherosclerosis in insulin-requiring diabetes patients.
- Trial name
- NCT00116545
- Testing
- troglitazone
- Where
- United States
- Volunteers
- 288 people
- Sponsor
- Parke-Davis
Diabetes Mellitus, Type 1
Diabetes Autoimmunity Withdrawn in New Onset Patients (DAWN)
The study is a prospective, randomized, double-blind, placebo-controlled, multi-center trial in subjects with new onset T1D.
- Trial name
- DAWN (NCT03794973)
- Testing
- TOL-3021
- Where
- United States
- Sponsor
- Tolerion, Inc.
Type 1 Diabetes, Hypoglycemia
Effect of ZT-01 on Glucagon During Hypoglycemia in Type 1 Diabetes Mellitus
The purpose of this study is to determine whether ZT-01 increases the glucagon response to hypoglycemia in type 1 diabetes (T1D).
- Trial name
- NCT05007977
- Testing
- ZT-01 low dose, ZT-01 high dose
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- Zucara Therapeutics Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.